HCC patient-derived tumor xenograft (PDX) models were also established from four HCC patient tissues, two with high and two with low ANLN m6A modifications, respectively, and employed these to assess the clinical potential of using DZNeP to target m6A modified ANLN (Fig. 6F). This evidence concerns the gene ANLN and neoplasm.